Minerva Neurosciences | NERV - Capitaux D'Emprunt





Capitaux D'Emprunt Changement Date
Acadia Pharmaceuticals USD 0 0 2025-03
Adma Biologics USD 69.33M 750K 2025-12
ALKERMES USD 285.82M 639K 2024-09
Alterity Therapeutics Limited AUD 103.21K 73.88K 2023-06
AstraZeneca USD 26.14B 19.58B 2025-12
BioCryst Pharmaceuticals USD 428.67M 234.31M 2025-12
Bristol-Myers Squibb USD 42.85B 1.62B 2025-12
Cipla INR 2.98B 454.6M 2025-09
Clal Biotechnology ILS 25.96M 18.48M 2023-12
Compugen USD 0 0 2024-12
CSL USD 10.42B 273M 2025-12
Eli Lilly USD 40.87B 5.6M 2025-12
Esperion Therapeutics USD 457.65M 9.5M 2025-12
GlaxoSmithKline GBP 14.71B 186M 2025-12
Grifols EUR 9.95B 722.93M 2025-12
Halozyme Therapeutics USD 2.14B 1.34B 2025-12
Ionis Pharmaceuticals USD 1.9B 1.87B 2025-12
J&J USD 39.44B 30M 2025-12
Merck USD 39.97B 6B 2025-09
Minerva Neurosciences USD 0 86.58M 2024-09
Neurocrine Biosciences USD 169.5M 500K 2023-03
Novartis USD 29.59B 5.35B 2025-12
Novavax USD 246.3M 200K 2025-12
Pfizer USD 57.41B 93M 2025-09
Roche Holding CHF 27.43B 966M 2025-12
Sanofi EUR 15.72B 2.45B 2025-12
Takeda JPY 4.27T 81.29B 2025-12
Vanda Pharmaceuticals USD 3.15M 3.15M 2024-12